158681-13-1 5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-methyl-N-(piperidin-1-yl)-1H-pyrazole-3-carboxamide hydrochloride AKSci J51761
 
 
Loading Please Wait...
  J51761    
5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-methyl-N-(piperidin-1-yl)-1H-pyrazole-3-carboxamide hydrochloride
, 95%
 



IDENTITY
CAS Number:158681-13-1
MDL Number:MFCD00934884
MF:C22H22Cl4N4O
MW:500.25
SPECIFICATIONS & PROPERTIES
Min. Purity Spec:95%
Physical Form:White to almost white crystalline powder
Long-Term Storage:Store at room temperature
HAZARDOUS MATERIALS INFORMATION
UN #:UN2811
Hazard Class:6.1; Poison
Packing Group:III
A hazmat fee may apply, depending on the amount ordered.

BIOLOGICAL INFO
Application(s):Selective antagonist of CB1
Form:HCl salt

REVIEW

 Rimonabant is a specific CB1 cannabinoid receptor antagonist. There is considerable evidence that the endocannabinoid (endogenous cannabinoid) system plays a significant role in appetitive drive and associated behaviours. It is therefore reasonable to hypothesize that the attenuation of the activity of this system would have therapeutic benefit in treating disorders that might have a component of excess appetitive drive or over-activity of the endocannabinoid system, such as obesity, ethanol and other drug abuse, and a variety of central nervous system and other disorders.

REFERENCES
[1]Gelfand EV, Cannon CP: Rimonabant: a selective blocker of the cannabinoid CB1 receptors for the management of obesity, smoking cessation and cardiometabolic risk factors. Expert Opin Investig Drugs. 2006 Mar;15(3):307-15.
[2] Xie S, Furjanic MA, Ferrara JJ, McAndrew NR, Ardino EL, Ngondara A, Bernstein Y, Thomas KJ, Kim E, Walker JM, Nagar S, Ward SJ, Raffa RB: The endocannabinoid system and rimonabant: a new drug with a novel mechanism of action involving cannabinoid CB1 receptor antagonism-or inverse agonism-as potential obesity treatment and other therapeutic use. J Clin Pharm Ther. 2007 Jun;32(3):209-31.
[3] Cahill K, Ussher M: Cannabinoid type 1 receptor antagonists (rimonabant) for smoking cessation. Cochrane Database Syst Rev. 2007 Oct 17;(4):CD005353.
[4] Maldonado R, Valverde O, Berrendero F: Involvement of the endocannabinoid system in drug addiction. Trends Neurosci. 2006 Apr;29(4):225-32. Epub 2006 Feb 17.

GHS

Pictograms

Signal Word
Danger

Hazard Statements
H301; H319

Precautionary Statements
P264; P270; P280; P301+P310; P305+P351+P338; P321; P330; P337+P313; P405; P501


Current as of June 16, 2021


Download SDS

For research use only. Not for diagnostic or therapeutic use. Not for human use. AK Scientific, Inc. does not sell to individuals. If you are a first-time customer, please email for review at least two official business documents issued by your local jurisdiction, state/province, or country.


CATEGORIES

 APIs and Bioactives > Weight Control


PubChem